On development of cell-based therapies that hopes and will make a major difference in reducing mortality in patients with acute respiratory distress syndrome, a major cause of acute respiratory failure in critically-ill patients. The researchers experience translating these therapies from scientific concept to clinical practice is featured in a series, a new resource for translational researchers that is managed by Institute related to clinical and translational studies.
A novel treatment into clinical trials is required. On a pre-clinical studies supporting proof-of-concept for a therapy using a type of stem cells, known as mesenchymal stem cells, could potentially treated with injury to a variety of epithelial organs, including the lung and kidney. Bone marrow-derived mesenchymal stem cells release proteins and lipids with potent anti-inflammatory effects as well as other growth factors that seem to enhance lung repair. Favorable pre-clinical data using these cells to treat injured lung tissue in vitro and in small and large animal models encouraged them to move into clinical trials. The struggle to implement this potentially life-saving therapy began with a search for clinical-grade mesenchymal stem cells.